Whalegun
Home

Halozyme Therapeutics HALO paid Forbes-Tate $60K for lobbying in Q4 2025 · Health Issues, Medicare

Trade details

Type
Lobbying report
Amount
$60,000
Quarter
Q4 2025
Stock
Halozyme Therapeutics HALO
Client
Halozyme Therapeutics
Reported
26/01/18

Up 0.0% from last quarter

What else happened in Halozyme Therapeutics around then

Filed or reported within 30 days of the trade day · 25/12/01~01/30

Halozyme Therapeutics's other lobbying reports

  • Halozyme Therapeutics

    LobbyingHalozyme Therapeutics

    $80K

    Reported 07/20

  • Halozyme Therapeutics

    LobbyingHalozyme Therapeutics

    $70K

    Reported 04/18

  • Halozyme Therapeutics

    LobbyingHalozyme Therapeutics

    $60K

    Reported 25/10/18

  • Halozyme Therapeutics

    LobbyingHalozyme Therapeutics

    $60K

    Reported 25/07/18

  • Halozyme Therapeutics

    LobbyingHalozyme Therapeutics

    $60K

    Reported 25/04/15

Halozyme Therapeutics HALO paid Forbes-Tate $60K for lobbying in Q4 2025 · Health Issues, Medicare | Whalegun